Search Results 191-200 of 15691 for TNF

  1. JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.

  2. Stem Cell Fistula Plug in Perianal Crohn's Disease - Mayo Clinic

    Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, and anti-TNF therapy are permitted. All patients should have ...

  3. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

    Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies. Exclusion Criteria: Current diagnosis of ...

  4. vasculitis Archives - Mayo Clinic News Network

    ... tumor necrosis factor inhibitors, part of a class of drugs called biologics. It comes down to proteins: specifically, a protein in the body that drives ...

  5. Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis - Mayo Clinic

    Biological agents: Anti-tumour necrosis factor (anti - TNF) therapy and / or vedolizumab; are not permitted within 8 weeks of the Screening Visit. All other ...

  6. A Study of the Use of a New Drug in People with Non-Alcoholic Steatohepatitis (NASH) or Non-Alcoholic Fatty Liver Disease (NAFLD) - Mayo Clinic

    Additionally, if subjects are taking drugs such Vit E, Ursodeoxycholic acid, Gemfibrozil, anti TNF therapies and probiotics will be allowed if on stable ...

  7. Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM - Mayo Clinic

    Receiving TNF pathway inhibitors, PI3 kinase inhibitors, systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the ...

  8. A Study to Assess the Effectiveness and Safety of Golimumab in Pediatric Participants With Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    Contraindications to the use of golimumab or infliximab or anti-tumor necrosis factor (TNF-alpha) therapy per local prescribing information. Participating ...

  9. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

    ... tumor necrosis factor (TNF) or anti-interleukin (IL)-6 agents are excluded * Participants still recovering from toxicity of prior anticancer therapy which ...

  10. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to cycle 1 day 1: Patients who have received acute, low dose, systemic immunosuppressant ...